Life Science Today

By: Noah Goodson PhD
Listen for free

  • Summary

  • Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
    © 2023 Life Science Today
    Show More Show Less
Economics Science
Show More Show Less
Episodes
  • Final Episode

    Final Episode
    Dec 20 2022

    This week, I have an announcement to make.

    Find out more at
    https://LifeScienceTodayPodcast.com


    About the Show
    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 
    Show More Show Less
    5 mins
  • Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago

    Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago
    Nov 30 2022

    Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyout

    Find out more at
    https://LifeScienceTodayPodcast.com

    Story References
    Sanofi/Takeda
    UniQure & CSL
    Fog Pharma
    Merck + Imago

    About the Show
    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 
    Show More Show Less
    9 mins
  • Indivior + Opiant, Regeneron + CytomX, Rezo, Provention

    Indivior + Opiant, Regeneron + CytomX, Rezo, Provention
    Nov 22 2022

    A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals

    Find out more at
    https://LifeScienceTodayPodcast.com

    Story References
    Indivior + Opiant
    Regeneron + CytomX
    Rezo
    Provention

    About the Show
    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 
    Show More Show Less
    6 mins

What listeners say about Life Science Today

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.